

A human fibrinogen variant with impaired *Staphylococcus aureus* binding function promotes host survival during septicemia in mice.

Jaap Koopman¹, Oscar Negron² Miranda Weggeman¹, Linda Huisman¹, Amanda Stang², and Matthew J. Flick²

¹Fibriant BV, 2333 CR Leiden, The Netherlands ²Cincinnati Children's Hospital Medical Center, Cancer and Blood Diseases Institute, Cincinnati, OH 45255

Staphylococcus aureus is a common gram-positive bacterium and a major public health threat. An important mechanism that contributes to S. aureus virulence is the ability of this pathogen to bind fibrin(ogen) and other host factors through an array of membrane bound bacterial virulence proteins. Our previous studies, using Fib $\gamma^{\Delta 5}$ mice that express a fibringen mutant lacking the binding motif for clumping factor A (ClfA) indicated that binding to this site is a major mechanism of pathogen virulence during acute septicemia. We hypothesized that the naturally occurring human fibringen γ' variant would have similar properties to fibring en $\gamma^{\Delta 5}$ mutant in that it would (i) lack S. aureus ClfA binding function and (ii) confer protection to acute septicemia in S. aureus infected hosts. Under stationary phase conditions, ClfA was the primary fibrinogen binding receptor whereas under exponential growth conditions binding was largely independent of ClfA. Surprisingly, both the ClfA dependent and independent binding to fibringen was almost completely abolished when using the human fibringen γ' variant (hFib γ'). Fibringendependent 'clumping' in solution was completely eliminated when analyzed using hFib γ' and was fully dependent on ClfA in both stationary and exponentially growing S. aureus. Reconstitution of fibrinogen-deficient mice or WT mice with hFib γ' provided a significant prolongation in host survival relative to mice reconstituted with hFib γ , indicating that hFib γ' confers protection alone and in combination with other fibringen species. These findings provide the proof-of-concept that naturally occurring fibringen variants could offer significant therapeutic potential against infection and potentially other diseases.

Presenting Author:

Matthew J. Flick, PhD Associate Professor Cancer and Blood Diseases Institute Division of Experimental Hematology and Cancer Biology Cincinnati Children's Hospital 3333 Burnet Avenue Cincinnati, OH 45229

Phone: 513-636-6628

Email: matthew.flick@cchmc.org